Metformin safe for most diabetics with kidney disease

Metform, a longtime and low-cost drug used to treat diabetes, is safe for most patients who also have chronic kidney disease, according to new research.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news

Related Links:

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
The Dietary Approaches to Stop Hypertension (DASH) diet lowers blood pressure and cardiovascular disease risk. In this issue, Banerjee et  al. report that the DASH diet is associated with lower risk of end-stage kidney disease in individuals with stage 3 chronic kidney disease and hypertension. This association was particulary strong among those with diabetes. The DASH diet may have an important role in preventing end-stage kidney di sease in select individuals with chronic kidney disease.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Commentary Source Type: research
Conclusions: Bariatric surgery increased miR 192 and miR 200 urinary levels, key anti-fibrotic microRNAs that could contribute to a renal-protective mechanism and may be of value as urinary biomarkers following surgery. These findings suggest that urinary microRNAs may represent potential novel biomarkers for obesity-associated renal function.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
CONCLUSIONS: Serum ALP level was positively and independently associated with baPWV in men and women, suggesting that an elevated ALP level may be a useful surrogate marker for arterial stiffness in adult men and women. PMID: 31092766 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
Authors: Mok CC Abstract INTRODUCTION: The metabolic syndrome (MetS) is now recognized as a chronic proinflammatory and prothrombotic state that aggravates insulin resistance, oxidative injury and cardiovascular risk. MetS is more prevalent in patients with systemic lupus erythematosus (SLE), a prototype of systemic autoimmune disease associated with premature atherosclerosis that cannot be accounted by traditional vascular risk factors alone. Dysregulation of the cytokines and adipokines is a common feature in both SLE and MetS, suggesting a complex relationship among autoimmunity, obesity, inflammation and athero...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
Changes in estimated glomerular filtration arte in patients with or without sodium –glucose cotransporter 2 inhibitors administration. AbstractAims/IntroductionThe risk of end ‐stage kidney disease increases in proportion to the decline in the estimated glomerular filtration rate (eGFR). Although protective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on the eGFR decline were shown in several large‐scale clinical trials, there are no studies invest igating patients with a high risk of end‐stage kidney disease. We investigated the efficacy and safety of SGLT2i in advanced renal d...
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Clinical Trial Source Type: research
Steroidal mineralocorticoid receptor antagonists (MRAs) are recommended for the treatment of heart failure (HF) and resistant hypertension, both common comorbidities in patients with diabetes and chronic kidne...
Source: BMC Nephrology - Category: Urology & Nephrology Authors: Tags: Research article Source Type: research
Publication date: Available online 14 May 2019Source: American Journal of Kidney DiseasesAuthor(s): Andrew S. Allegretti, Wenbin Zhang, Wenjiong Zhou, Tara K. Thurber, Scott P. Rigby, Cynthia Bowman-Stroud, Carlos Trescoli, Pierre Serusclat, Mason W. Freeman, Yuan-Di C. HalvorsenRationale &ObjectiveHyperglycemia exacerbates the progression of chronic kidney disease (CKD), but most glucose-lowering therapies do not address morbidities associated with CKD. Sodium/glucose cotransporter 2 (SGLT2) inhibitors offer potential benefits to patients with diabetes and CKD, but their effectiveness may be diminished with ...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Iron parameters have not been well characterized in pre-dialysis patients with chronic kidney disease, and it remains unclear if abnormal iron balance is associated with increased mortality. Therefore, we performed a historical cohort study using data from the Veterans Affairs Corporate Data Warehouse to evaluate the relationship between iron status and mortality. We identified a pre-dialysis chronic kidney disease cohort with at least one set of iron indices between 2006-2015. The cohort was divided into four iron groups based on the joint quartiles of serum transferrin saturation (percent) and ferritin concentration (ng/...
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Clinical Investigation Source Type: research
Bardoxolone methyl attenuates inflammation by inducing Nrf2 and suppressing NF- κB. The Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) trial was a phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial in 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney dis ease. BEACON was terminated because of safety concerns, largely related to a significant increase in early heart failure events in patients randomized to bardoxolone methyl.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Clinical Trial Source Type: research
More News: Chronic Kidney Disease | Diabetes | Endocrinology | Fortamet | Health | Metformin | Urology & Nephrology